D&B D‐U‐N‐S® RegisteredTM & USA FDA Labeler Code
Eminence Biotech Corporation Limited
D&B D‐U‐N‐S® Number: 07‐853‐1141
USA FDA Eminence Biotech’s Labeler Code: 53304
Btech Biochem Corporation
D&B D‐U‐N‐S® Number: 65‐623‐0229
USA FDA Btech’s Labeler Code: 53447
D & B: The Dun & Bradstreet Corporation, a public company that licenses information on business and corporations for use in credit decisions, business to business marketing and supply chain management. (Since 1841)
USA FDA: U.S. Food and Drug Administration
1999 Primary laboratory established in USA in 1999.
2002 Successfully developed the most advanced technologies in the world, including transdermal absorption, technology of nanosized organic material, technology of micro‐potential detecting and eliminating for cells, technology of fat selecting and processing for liposome.
2002 BTECH BIOCHEM CORPORATION (sister company of Eminence Biotech Co. Ltd.) established and registered in Taiwan in December, as a production base.
2003 Eminence Biotech Co. Ltd. established and registered in USA in January, and authorized BTECH BIOCHEM CORPORATION to apply the technologies for the production of the relevant products.
2004 BTECH BIOCHEM CORPORATION produced series products of biochem nano photo catalyst, nano neuron bio‐defense liquid, nano joint bio‐defense liquid and nano anti‐menstrual pain liquid, etc., which acquired the Golden award of Quality granted by Republic of China Consumers Association as well as acquired the National Golden award of Quality Assurance for those products at the same time.
2004 Eminence Biotech Co. Ltd. formally announced in February the success of product developed for curing gingivitis and periodontal disease.
2004 Eminence Biotech Co. Ltd. formally announced in February the success of products developed for prompt curing the ulcer of internal membrane in mouth cavity and the gums inflammation.
2004 Eminence Biotech Co. Ltd. formally announced in May the success of products developed for curing the allergic rhinitis.
2005 Nine major products were successfully developed to the market (codes as EB201 / EB301 / EB302 / EB303 / EB305 / EB306 / EB606 / EB801 / EB802) which were registered in U.S. PDR (PHYSICIANS’ DRUG REFERENCE manual 2005).
2006 Based on the successfully developed cutting‐edge technologies for drugs, we developed the extending drug‐free articles for daily use as follows.
1. Shampoo – to prevent hair from abnormal losing and to delay the hair from getting gray
2. Body cleanser – to eliminate micro‐potential and to refresh in the meantime
3. Cosmetics – to process traditional cosmetics by cutting‐edge technologies to acquire better performance
2007 Devoted to the research of toxalbumin such as venin and venom (of scorpion), expecting to replace the botulinus toxins which containing higher toxicity, in order to be applied more safely for rheumatism and beauty treatment.
2008 With the theory of cell rehabilitation, devoted to the research of remedy for myopia (short‐sightedness), hyperopia (far‐sightedness) and presbyopia.
2009 Devoted to the rejuvenation research of epidermis and dermis cells activity
2011 Successfully developed the products as eye cream and lifting essence with the performance of instant rejuvenation. Devoted to the research in the effectiveness of natural botanical foods to the fundamental functions of human body
2012 in November, National drug code (NDC) for EB302 (ARTHRITIS RELIEF SPRAY) x 50mL “NDC 53304‐0302”, and EB306 (ALLERGIC RHINITIS RELIEF ) x 15mL “NDC 53304‐0306” being listed and approved by USA FDA.
2013 in March, National drug code (NDC) for EB301AP (PAIN RELIEF SPRAY) x 100mL “NDC 53304‐0301‐1”, and EB301CT (BRUISE PAIN RELIEF SPRAY) x 100mL, “NDC 53304‐1301” being listed and approved by USA FDA. in May, National drug code (NDC) for EB301AP (PAIN RELIEF SPRAY) x 15mL “NDC 53304‐0301‐3” with volume of 15mL as portable package being listed and approved by USA FDA.